Ajanta Pharma Intrinsic Value
Ajanta Pharma (AJANTPHARM) median intrinsic value is ₹1964.45 from 10 valuation models (range ₹1011–₹6739), vs current price ₹3369.50 — -41.7% downside (Trading Above Calculated Value), margin of safety -71.5%. For current market price and key ratios, visit Ajanta Pharma stock price NSE.
AJANTPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Ajanta Pharma intrinsic value across 10 models vs current price ₹3369.50 — upside/downside and value range per method. Read AJANTPHARM dividend payout details for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1878.80 | ₹1503.04 - ₹2254.56 | -44.2% | EPS: ₹85.40, Sector P/E: 22x |
| Book Value Method | asset | ₹3621.60 | ₹3259.44 - ₹3983.76 | +7.5% | Book Value/Share: ₹1810.80, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4745.60 | ₹4271.04 - ₹5220.16 | +40.8% | Revenue/Share: ₹2372.80, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹6320.00 | ₹5688.00 - ₹6952.00 | +87.6% | EBITDA: ₹1580.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1964.45 | ₹1571.56 - ₹2357.34 | -41.7% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1010.85 | ₹909.76 - ₹1111.94 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1319.43 | ₹1187.49 - ₹1451.37 | -60.8% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹6739.00 | ₹6065.10 - ₹7412.90 | +100.0% | ROE: 23.6%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1865.33 | ₹1678.80 - ₹2051.86 | -44.6% | EPS: ₹85.40, BVPS: ₹1810.80 |
| Dividend Yield Method | dividend | ₹1120.00 | ₹1008.00 - ₹1232.00 | -66.8% | DPS: ₹28.00, Target Yield: 2.5% |
AJANTPHARM Intrinsic Value vs Market Price — All Valuation Models
Ajanta Pharma fair value range ₹1011–₹6739 vs current market price ₹3369.50 across 10 valuation models. Analyse AJANTPHARM shareholding pattern to track promoter, FII and institutional holdings.
AJANTPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Ajanta Pharma median intrinsic value ₹1964.45, current price ₹3369.50 — Trading Above Calculated Value by 41.7%, margin of safety -71.5%.
What is the intrinsic value of AJANTPHARM?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Ajanta Pharma (AJANTPHARM) is ₹1964.45 (median value). With the current market price of ₹3369.50, this represents a -41.7% variance from our estimated fair value.
The valuation range spans from ₹1010.85 to ₹6739.00, indicating ₹1010.85 - ₹6739.00.
Is AJANTPHARM undervalued or overvalued?
Based on our multi-method analysis, Ajanta Pharma (AJANTPHARM) appears to be trading above calculated value by approximately 41.7%.
AJANTPHARM Financial Health — Key Ratios vs Industry Benchmarks
Ajanta Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 17.62 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 23.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.96x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AJANTPHARM Cash Flow Quality — Operating & Free Cash Flow
Ajanta Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹529 Cr | ₹315 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹1,157 Cr | ₹969 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹785 Cr | ₹785 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹792 Cr | ₹512 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹562 Cr | ₹525 Cr | Positive Free Cash Flow | 8/10 |